TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Pennant Group Inc (PNTG)

Healthcare Medical Care Facilities
40.30 $
-2.0% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Pennant Group Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 9 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
41.10$
Open
40.90$
Day High
41.20$
Day Low
39.50$
Volume
217,085shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
22.10 $ 42.00 $
08/01/2025 07/28/2026

Current price 40.30 $ — 92% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
1.4$B
Shares Outstanding
35Mio.
Float
95.0%
Beta
1.3

Performance

Perf. 1M
5.80%
Perf. 3M
21.80%
Perf. 6M
24.30%
YTD Performance (%)
21.60%
52-Week-High Distance
-4.5%
Perf. 1Y
81.87%
Perf. 3Y
251.22%
Perf. 5Y
17.83%
Perf. Since Inception
167.20%

Technical Indicators

MA 38 Days
37.70$
MA 50 Days
36.60$
MA 200 Days
31.40$
RSI (14)
55.5
Volatility 30 Days
31.7%
Volatility 250 Days
39.0%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
46.9
Forward P/E
30.2
PEG
2.3
P/B
4.0
P/S
1.3
EV/EBITDA
28.0
Price/FCF
29.1

Profitability

Gross Margin
19.6%
EBIT Margin
Net Margin
3.0%
Return on Equity
10.0%
Return on Assets
4.1%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
1.3
Altman Z″
4.74
weak
Piotroski
2 out of 9

Growth

Sales Growth Last Quarter
36.00%
EPS Growth Last Quarter
9.10%
Sales Growth (Year)
36.31%
Forward Sales Growth
7.78%
Forward EPS Growth
17.60%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
RS Rating
63
EPS Rating
58
weak
Piotroski
2 out of 9
Fundamental Rating
B (56 out of 100)
Altman Z″
4.74

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Growth Score

3 of 10 Weak growth

Ten checks against the annual reports — each one passed counts a point.

  • Revenue grows by more than 15% a year over three years 26.0% passed
  • More than 10% revenue growth is expected for the coming year 7.8% failed
  • Share count grows by less than 3% a year 5.4% failed
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 39.1% failed
  • Gross margin at 40% or higher and without meaningful erosion 12.9% failed
  • Goodwill from acquisitions does not grow faster than revenue 24.5% failed
  • Net debt below twice EBITDA 7.2 x EBITDA failed
  • Operating cash flow covers the profits of the last three years 55 m passed
  • Return on capital at 15% or higher, or up versus two years ago 6.3% passed
  • Insiders hold at least 10% or are net buyers 5.0% failed

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 40.30 $
Price Target (average) 45.00 $

The price target sits 11.7% above the current price.

Consensus
Sell
Analyst Ratings
4
Distribution of Recommendations
Strong Buy 1
Buy 1
Hold 2
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 1.35 1.33 – 1.38 1,165 14.8% 7
12/31/2027 1.60 1.50 – 1.78 1,256 18.0% 7

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

5. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
0.28 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 188.9 $M Q4 2025: Q1 · 209.8 $M Q1 2025: Q2 · 219.5 $M Q2 2025: Q3 · 229.0 $M Q3 2025: Q4 · 289.3 $M Q4 2026: Q1 · 285.4 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.16 13.30 189 29.40 3.00 21 17
2025: Q1 0.22 36.90 210 33.70 3.70 -21 -23
2025: Q2 0.20 8.40 220 30.10 3.20 35 32
2025: Q3 0.17 -12.90 229 26.80 2.70 14 11
2025: Q4 0.24 49.50 289 53.20 3.00 21 14
2026: Q1 0.24 7.90 285 36.00 3.00 -3 -9
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 217 13 8 0.28 16
2017 251 15 10 0.35 17 55 88
2018 286 21 16 0.56 23 56 98
2019 339 6 3 0.09 10 71 448
2020 391 19 16 0.52 50 97 507
2021 440 5 3 0.09 -18 110 530
2022 473 13 7 0.22 9 121 512
2023 545 25 13 0.44 33 140 540
2024 695 38 23 0.71 39 293 680
2025 948 51 30 0.84 48 333 968

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

The Pennant Group, Inc. bietet Gesundheitsdienstleistungen in den USA an.

Employees9,700
HeadquartersEagle, ID
Address1675 East Riverside Drive, 83616 Eagle, United States
Phone208 401 1400
Websitepennantgroup.com
IPO Date1. Oct 2019
ISINUS70805E1091

Management

Management
Name Title Birth Year
Brent J. Guerisoli CEO & Chairman 1981
John J. Gochnour President & COO 1984
Lynette B. Walbom CPA Chief Financial Officer 1978
Kirk S. Cheney J.D. Executive VP, General Counsel & Corporate Secretary 1982
Jason P. Steik Chief Clinical Officer 1984
Andrew Rider President of Pinnacle Senior Living LLC

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
15. Jul 2026 Morris Gregory K Sr. Director Other 1,900 0.00
15. Jul 2026 Snapper Suzanne D. Director Other 1,900 0.00
15. Jul 2026 Nackel John G. Director Other 1,900 0.00
15. Jul 2026 Christensen Christopher R. Director Other 1,900 0.00
15. Jul 2026 Lamb Scott E Director Other 2,400 0.00
15. Jul 2026 Smith Barry M Director Other 1,900 0.00
15. Jul 2026 Covey Stephen M R Director Other 1,900 0.00
10. Jul 2026 Guerisoli Brent Chief Executive Officer Sell 3,159 41.57 131,304
10. Jul 2026 Guerisoli Brent Chief Executive Officer Other 6,248 4.54 28,366
7. Jul 2026 Guerisoli Brent Chief Executive Officer Sell 3,165 40.51 128,214

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?